Australia Cancer Biomarkers Market Growth Analysis - Forecast Trends and Outlook (2025-2034)

Key Market Trends and Insights

• By type, the genetic biomarkers segment dominated the market in terms of revenue share during the historical period.
• Based on cancer type, the breast cancer segment held a significant share of the market in terms of revenue during the historical period.
• The application outlook showed that the diagnostics segment dominated the market in terms of revenue share during the historical period.

Market Size and Forecast

• Market Size (2024): AUD 1.46 billion
• Projected Market Size (2034): AUD 3.82 billion
• CAGR (2025-2034): 10.10%

Australia Cancer Biomarkers Market Overview

Cancer biomarkers play a crucial role in advancing oncology by enabling early detection, guiding treatment decisions, and supporting the development of targeted therapies. They serve as vital tools for precision medicine, improving patient outcomes through personalized approaches. The market has been witnessing steady growth, driven by rising cancer prevalence, increasing adoption of advanced diagnostic technologies, and expanding research initiatives. Strong government support, collaborations between healthcare providers and biotechnology firms, and a growing focus on personalized medicine further contribute to market expansion. The market was valued at AUD 1.46 billion in 2024.

Australia Cancer Biomarkers Market Growth Drivers

Escalating Cancer Burden to Fuel the Growth in the Market

The rising incidence of cancer is one of the primary growth drivers of the market. The Australian Institute of Health and Welfare (AIHW) reported that cancer diagnoses increased from approximately 88,000 cases in 2000 to an estimated 169,000 cases in 2024, representing a 93% surge over 24 years. Moreover, the annual number of cancer cases is projected to exceed 200,000 by 2034, driven mainly by population expansion and an aging demographic. This sharp rise in cancer prevalence is expected to accelerate the adoption of advanced biomarkers, thereby strengthening market growth.

Australia Cancer Biomarkers Market Trends

Some of the trends in the market include advancements in immune-based biomarkers and an increasing focus on liquid biopsies.

Advancements in Immune-Based Biomarker Panels to Enhance Market Growth

The market is witnessing a strong trend toward the development of immune-based biomarker panels that improve treatment personalization. In May 2025, researchers at Monash University introduced a novel biomarker panel designed to predict bladder cancer patients’ response to immunotherapy, highlighting the growing shift from generalized approaches to precision oncology. This innovation reflects increasing emphasis on early identification of treatment resistance and optimization of therapeutic strategies. Such advancements are expected to strengthen clinical adoption, ultimately driving market growth in Australia’s cancer biomarkers sector.

Rising Focus on Liquid Biopsies to Boost Australia Cancer Biomarkers Market Demand

The increasing emphasis on liquid biopsy development for early detection, monitoring, and treatment guidance in oncology is a key trend shaping the market. In June 2025, the recognition of Edith Cowan University’s Cancer Blood Biomarkers Study through state funding highlighted the rising importance of blood-based biomarkers in cancer research and clinical applications. This initiative demonstrates the strong support for biomarker discovery and validation, reflecting a broader shift toward precision health solutions. Such advancements are expected to significantly enhance cancer biomarker adoption and drive market growth in Australia.

Australia Cancer Biomarkers Market Share

Breast Cancer to Hold a Prominent Share in the Segmentation by Cancer Type

There are various cancer types considered in the market, including lung cancer, breast cancer, leukemia, melanoma, colorectal cancer, prostate cancer, and others. Among these, breast cancer is anticipated to lead due to its growing incidence and substantial patient base. Data from the Australian Institute of Health and Welfare estimated 21,194 new cases in 2024, accounting for 13% of all cancer diagnoses. With a survival rate of 92.3% and more than 83,000 people living with the disease, breast cancer presents the strongest demand for advanced biomarker applications in diagnosis, prognosis, and therapy monitoring.

Leading Players in the Australia Cancer Biomarkers Market

The key features of the market report comprise funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Illumina, Inc.

Illumina, Inc. is a leading innovator in DNA sequencing and array-based technologies, widely recognized for advancing precision medicine and cancer diagnostics. In August 2024, the company received U.S. FDA approval for its TruSight™ Oncology Comprehensive test, a next-generation sequencing-based in vitro diagnostic kit that profiles over 500 genes in solid tumors. The test, which includes companion diagnostic approvals for Bayer’s VITRAKVI® and Lilly’s RETEVMO®, strengthens Illumina’s role in the cancer biomarkers market by enabling broader access to targeted therapies and comprehensive tumor profiling.

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. plays a significant role in the cancer biomarkers market through its ongoing innovations in biomarker testing. The company has actively emphasized the importance of biomarker testing in lung cancer care, as evident in its recent initiatives and publications from 2023. By advancing biomarker-based diagnostics, Roche is strengthening personalized cancer treatment approaches and contributing to improved patient outcomes globally.

Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. plays a significant role in the cancer biomarkers market through its advanced biomarker discovery and analysis solutions. The company’s Bio-Plex® suspension array system enables multiplex detection of cytokines, chemokines, growth factors, and phosphoproteins, which are critical in cancer research and diagnostics. By supporting the identification of disease progression and drug response, Bio-Rad contributes to improving cancer biomarker research and accelerating therapeutic development.

Qiagen N.V.

Qiagen N.V. plays a significant role in the cancer biomarkers market with its advanced oncology solutions that support cancer research and clinical diagnostics. The company offers a broad portfolio including liquid biopsy technologies, tumor mutational burden profiling, RNA biomarker analysis, and next-generation sequencing tools to enhance early detection and precision medicine. Qiagen’s innovations in biomarker detection, diagnostic testing, and companion diagnostics strengthen its position in driving cancer research and improving patient outcomes.

Other key players in the market include Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Hologic, Inc., Quest Diagnostics Clinical Laboratories, Inc., and Charles River Laboratories.

Key Questions Answered in the Australia Cancer Biomarkers Market Report

• What was the Australia cancer biomarkers market value in 2024?
• What is the Australia cancer biomarkers market forecast outlook for 2025-2034?
• What are the major factors aiding the Australia cancer biomarkers market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major Australia cancer biomarkers market trends?
• Which type is expected to dominate the market segment?
• Which cancer type is projected to lead the market segment?
• Which application is anticipated to drive the market segment?
• Which profiling technology is projected to lead the market segment?
• Which end user is likely to dominate the market segment?
• Who are the key players involved in the Australia cancer biomarkers market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?